期刊文献+

右美托咪定对下肢手术使用止血带的血流动力学的影响 被引量:5

Effect of Dexmedetomidine on the Tourniquet-induced Hyperdynamic Response in Patients Undergoing Lower Limb Surgeries
原文传递
导出
摘要 目的:观察右美托咪定(dexmedetomidine,Dex)对下肢手术使用止血带的血流动力学的影响。方法:选择择期在我院行下肢手术的患者60例,ASA I~Ⅱ级,随机分为2组,即右美托咪定组(dexmedetomidine,D组)和对照组(control,C组),每组30例,两组均选择腰硬联合麻醉。麻醉成功后,D组于上止血带前15 min,用微量泵给予Dex负荷量0.8μg/kg,10 min静脉泵入,之后输注速度设定为0.4μg.kg-1.h-1,直至止血带放气;C组用生理盐水代替右美托咪定,用药方法同D组。记录两组药物给负荷量之前(T0)、止血带充气前(T1)、止血带充气后15 min(T2)、止血带充气后30 min(T3)、止血带充气后45 min(T4)、止血带充气后60 min(T5)及止血带放气后5 min(T6)的平均动脉压(MAP)、心率(HR)及血氧饱和度(SPO2);记录两组高血流动力学的发生率及所用血管活性药物的量。结果 :用药前,两组患者的MAP、HR及SPO2比较,差异均无统计学意义(P>0.05)。D组患者给予负荷量后,T2~T5各时点MAP均较T1显著升高(P<0.05),而T6时MAP下降,与T1比较无明显差异(P>0.05);T4~T6各时点HR均较T1显著升高(P<0.05),各时点SPO2比较均无统计学意义(P>0.05)。C组在T2~T6各时点MAP和HR均较T1显著升高(P<0.05),各时点SPO2比较均无统计学意义(P>0.05)。T2、T4和T6各时点D组患者的MAP具显著低于C组(P<0.05),T1~T6各时点HR均显著低于C组(P<0.05)。D组T1时HR显著低于T0时(P<0.05)。C组和D组患者高血流动力学反应的发生率分别为66.7%和20%,C组明显高于D组(P<0.01)。两组患者尼卡地平和阿托品的用量差异均无统计学意义(P>0.05),但D组麻黄碱的用量明显高于C组(P<0.0 5),两组患者均未应用艾司洛尔处理。结论:Dex可减少下肢手术使用止血带时引起的血流动力学高反应的发生。 Objective: To evaluate the effects of dexmedetomidine on the tourniquet-induced hyperdynamic response during combined spinal anesthesia (CSEA). Methods: 60 patients ofASA I - II undergoing lower limb surgeries Utider CSEA were allocated randomly into two groups, 30 cases in each group: dexmedetomidine group (Group D) and control group (Group C). Unddr CSEA, the group D was received a loading dose of dexmedetomidine (0.8 μg/kg, over 10 min) followed by continuous infusion of dexmedetomidine (0.4 μg .kg .h^-1) until tourniquet deflation. The group C received normal saline instead. Tourniquet-induced changes in hettiodynatrlic parameters, including heart rate (HR), mean arterial pressure (MBP) were compared between two groups. ResUlts: Before drug administration, no significant difference of hemodynamic parameters, including HR, MAP and SPO2 was observed between the two groups (P〉0.05). MAP of group D at T2, T3, T4 and T5 were significantly higher than that of T1 after a bolus dose of dexmedetomidine (0.8 μg/kg) (P〈0.05), which was lower slightly at T6 than that at T 1 (P〉0.05). HR of group D at T4, T5 and T6 were significantly higher than that at T1, and it was significantly lower at TI than that at TO after a bolus dose of dexmedetomidine (0.8 μg/kg) (P〈0.05). MAP and HR of group C at T2, T3, T4, T5 and T6 were higher than that at T1 (P〈0.05). MAP of group D at T2, T4 and T6 were lower than than of group C(P〈0.01). HR of group D from T1 to T6 were lower than that of group C(P〈0.05). The incidence of hyperdynamic response iti the group C was significantly higher than that in the group D (66.7% versus 20.0%; P〈0.01). The total consumption of nieardipine and atropine was comparable in these two groups (P〉0.05). Howe^cer, the total ephedrine consumption was higher in group D than in group C (P〈0.05) None of the cases received esmolol. Conclusion: Dexmedetomidine attenuated tourniquet-induced hyperdynamic response in combined spinal anesthesia patients undergoing lower limb surgeries.
出处 《现代生物医学进展》 CAS 2013年第11期2096-2099,共4页 Progress in Modern Biomedicine
基金 2012年十堰市科学技术研究与开发项目计划(078S)
关键词 右美托咪定 止血带 下肢手术 高血流动力学反应 Dexmedetomidine Tourniquet Lower limb surgery High hemodynamic response
  • 相关文献

参考文献20

  • 1Kaufman RD, Walts LF. Tourniquet-induced hypertension[J]. Br J Anaesth,1982,54(3):333-336.
  • 2Gielen MJ, Stienstra R. Tourniquet hypertension and its prevention: A review[J]. Reg Anesth,1991,16(4):191-194.
  • 3Tetzlaff JE, O'Hara Jr J, Yoon HJ, et al. Tourniquet-induced hypertension correlates with autonomic nervous system changes detected by power spectral heart rate analysis] J]. J Clin Anesth, 1997,9 (2):138-142.
  • 4Zalunardo MP, Serafino D, Szelloe P, et al. Preoperative clonidine blunts hyperadrenergic and hyperdynamic responses to prolonged tourniquet pressure during general anesthesia[J]. Anesth Analg,2002,9 4(3):615-618.
  • 5Bylund DB. Subtypes of alpha 1- and alpha 2-adrenergic receptors[J]. FASEB J,1992,6(3):832-839.
  • 6Khan ZP, Ferguson CN, Jones RM. Alpha-2 and imidazoline receptor agonists: Their pharmacology and therapeutic role[J]. Anaesthesia, I 9 99,54(2): 146-165.
  • 7Sato K, Kimura T, Nishikawa T, et al . Neuroprotective effects of a combination of dexmedetomidine and hypothermia after incomplete cerebral ischemia in rats(J]. Acta Anaesthesiol Scand,2010,54(3):377 -382.
  • 8Hisako Okada, Tadayoshi Kurita, Toshiaki Mochizuki, et al. The cardioprotective effect of dexmedetomidine on global ischaemia in isolated rat hearts[J]. Resuscitation,2007,74(3):538-545.
  • 9Hanci V, Yurdakan G, Yurtlu S, et al. Protective effect of dexmedetomidine in a rat model of a-naphthylthioureae induced acute lung injury[J]. Journal of surgical research,2012, 178(1 ):424-430.
  • 10Kam PC, Kavanagh R, Yoong FF. The arterial tourniquet: Pathophysiological consequences and anaesthetic implications[J]. An?aesthesia,200 1,5 6(6): 5 34-545.

二级参考文献58

  • 1[1]Khan ZP,Ferguson CN,Jones RM.Alpha-2 and imidazoline receptor agonists:their pharmacology and therapeutic role[J].Anesthesia,1999;54:146-165.
  • 2[2]Kamibayashi T,Maze M.Clinical uses of alpha 2-adrenergic agonists[J].Anesthesiology,2000;93:1345-1350.
  • 3[3]Calzada BC,De Artinano AA.[alpha]2-Adrenoreceptor subtypes[J].Pharmacol Res,2001;44:195-208.
  • 4[4]Hunter JC,Fontanna DJ,Hedley LR,et al.Assessment of the role of alpha 2-adrenoceptor subtypes in the antinociceptive,sedative and hypothermic action of dexmedetomidine in transgenic mice[J].Br J Pharmacol,1997;122:1339-1344.
  • 5[5]Nelson LE,Lu J,Guo TZ,et al.The α2-Adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects[J].Anesthesiology,2003;98:428-436.
  • 6[6]Coull JT,Jones M,Egan T,et al.Attentionla effects of noradranaline vary with arousal level:selective activation of thalamie pulvinar in humans[J].Neuro Image,2004;22:315-322.
  • 7[7]Eisenach JC.[Alpha]2 agonists and analgesia[J].Exp Opin Invest Drugs,1994;3:1005-1010.
  • 8[8]Ma D,Rajakumamswamy N,Maze M.Alpha2-Adrenoceptor agonists:shedding light on neuroprotection?[J].Br Med Bull,2005;71:77-92.
  • 9[9]Ebert TJ,Hall JE,Barney JA,et al.The effects of increasing plasma concentrations of dexmedetomidine in humans[J].Anesthesiology,2000;93:382-394.
  • 10[10]Ramsey MA,Luterman DL.Dexmedetomidine as a total intravenous anesthestic agent[J].Anesthesiology,2004;101:787-781.

共引文献500

同被引文献33

引证文献5

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部